Diabetes & Metabolism

New NephSAP Issue - "Chronic Kidney Disease and Progression"

NephSAP Volume 18, Number 4, September 2019

Chronic Kidney Disease and Progression

ASN Weighs in on ESRD Treatment Choice Model in Letter to CMS

Reducing the benchmark for the combined home dialysis and transplant rate and allowing for incremental achievement of the benchmark, incentivizing and investing wisely to ensure needed practice transformation, and delaying the start date of the ESRD Treatment Choice Model (ETC) until April 2020 are among the recommendations for adjustments to the model set forth in a letter sent to CMS Administrator Seema Verma on behalf of ASN and its members from President Mark E. Rosenberg, MD, FASN.

Advancing Nephrology: Division Leaders Advise ASN

Asserting the value of nephrology

Physician productivity and compensation

Financial support of educational effort

Recruitment, retention, diversity and inclusion

Ensuring that Nephrology fellowship programs provide quality training in all aspects of kidney care

ASN Policy Q&A on the Advancing American Kidney Health initiative: Part 2

In order to double the number of kidneys available for transplant by 2030, the Administration is looking to increase the utilization of available organs from both deceased and living donors in multiple ways including, but not limited to:...

Diabetes and Kidney Disease 2019: August Special Section

Capture_title_0.PNGDiabetes is the second most common cause of kidney failure in the United States. Diabetic Kidney Disease (DKD) encompasses structural and functional abnormalities involving the kidneys. Clinically, these changes result in hypertension, proteinuria, and progressive decline in kidney function, ultimately leading to ESKD. Diabetic kidney disease accounts for more than 40% of all ESKD In the United States.

Dr. Reshma Kewalramani named incoming president and CEO of Vertex Pharmaceuticals, former member ASN KHI Board of Directors

Announced July 25, Dr. Reshma Kewalramani will be promoted to president and CEO of Vertex Pharmaceuticals. She is currently the chief medical officer for the company and was previously a practicing nephrologist who earned her medical doctorate at Boston University and trained at Bigham & Women’s Hospital.

Dr. Kewalramani will be the first woman to run a large biotechnology firm. Vortex’s share price “rose 360% and its sales doubled to $3 billion annually” under the previous CEO, largely due the company’s pharmaceuticals used to treat cystic fibrosis.

Breaking: HHS announcing rollout of new kidney strategy July 10th

Wednesday, July 10, the Trump administration will announce a new Department of Health and Human Services-wide (HHS) Comprehensive Kidney Care strategy. ASN and other kidney care groups have been working and meeting with Administration officials, including Secretary Alex M. Azar, II, all year providing input and recommendations for inclusion of in the new strategy.

Interview: Dr. Michael Allon, Editor-in-Chief of the new ASN journal, Kidney360

Kidney News Online (KNO) recently spoke with Michael Allon, MD, the inaugural Editor-in-Chief for the newest journal from the American Society of Nephrology, Kidney360. As the open access, online only journal will begin accepting manuscripts in September 2019, KNO wanted to learn more...

Kana Miyata, MD - Ben J. Lipps Research Fellowship Award (2019)

Name: Kana Miyata, MD

Institution: CRCHUM, University of Montreal

Grant: Ben J. Lipps Research Fellowship Award (2019)

Project Title: Novel Role of Heterogeneous Nuclear Ribonucleoprotein F (hnRNP F) in Regulation of Sodium-Glucose Cotransporter 2 (Sglt2) Expression in Diabetes
 

How would you sum up your research in one sentence?

Q&As with ASN Foundation Grant Recipients 2019

The following articles are brief Q&A sessions with American Society of Nephrology (ASN) grant recipients. The sessions explore what research the individual is undertaking with the grant funds, their hopes for the research, career goals, and advice for others interested in applying for these grant funds.

Pages